OCT 29, 2014 6:00 AM PDT

Expanding the scope of RNA-Seq to archival FFPE samples

Speaker
  • Research & Development Scientist, Thermo Fisher Scientific
    Biography
         Dr. Bramlett leads the RNA Sequencing Applications Team at Life Sciences Solutions, Thermo Fisher Scientific. She guides the Research & Development effort focused on creating innovative sequencing and data analysis solutions for the detailed analysis of RNA. Prior to joining Thermo Fisher Scientific, Dr. Bramlett was a drug development scientist at Eli Lilly and Company, where she led a team of scientists specializing in gene regulation and nuclear receptor biology to identify novel drug targets. Dr. Bramlett built her background and experience in gene regulation through prior academic positions at Baylor College of Medicine and the M.D. Anderson Cancer Center. Kelli holds an undergraduate degree in Chemistry from Rice University in Houston, Texas, and a masters degree in Pharmacology from the Indiana University School of Medicine in Indianapolis, Indiana.

    Abstract

    As next-generation sequencing (NGS) platforms advance in their speed, ease-of-use, and cost-effectiveness, many translational researchers are transitioning from microarrays to RNA sequencing (or RNA-seq) for their gene expression analysis needs. RNA-seq goes beyond differential gene expression to provide fundamental insights into how genomes are organized and regulated. New RNA-seq solutions now offer higher sensitivity, increased sample number flexibility, and the ability to analyze highly degraded or rare samples from as little as 10 ng of input RNA. Dr. Bramlett will discuss how NGS and RNA-seq can be applied for the discovery of new tumor biomarkers in archived formalin-fixed, paraffin-embedded (FFPE) samples.


    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    NOV 10, 2020 7:00 AM PST
    C.E. CREDITS
    NOV 10, 2020 7:00 AM PST
    DATE: November 10, 2020 TIME: 7:00am PDT, 10:00am EDT Automation can provide tremendous benefits such as increased pipetting precision and accuracy, productivity, and throughput. Numerous wo...
    SEP 03, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 03, 2020 9:00 AM PDT
    DATE: September 3, 2020 TIME: 09:00am PT, 12:00pm ET xxx Learning Objectives: xxx Webinars will be available for unlimited on-demand viewing after live event. LabRoots is approved as a provi...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    Loading Comments...
    Show Resources
    Attendees
    • See more